Amgen Inc. beat Wall Street’s expectations on Tuesday with its second-quarter financial results.
Rand Medical Building in Simi Valley has sold for $2.9 million, according to commercial brokerage Marcus & Millichap in Calabasas.
Amgen Inc. on Thursday announced that the U.S. Food and Drug Administration has accepted the biologics license application for Aimovig, a drug for prevention of migraine.
Amgen Inc. on Tuesday announced a collaboration agreement with Array BioPharma for development of drugs for autoimmune disorders.
MannKind Corp. on Monday announced that Steven Binder has joined the company as chief financial officer.
Amgen Inc.’s leukemia drug Blincyto has received full approval from the U.S. Food and Drug Administration, the company has announced.
MannKind Corp. on Wednesday announced that Patrick McCauley will join the company as chief commercial officer.
Cure Pharmaceuticals on Tuesday announced that it has signed a memorandum to enter into a research collaboration with two Israeli companies.
Simulation Plus Inc. on Monday reported fiscal third-quarter earnings that showed rising revenue and net income.
Sienna Biopharmaceuticals Inc. on Monday filed paperwork with the Securities and Exchange Commission for an initial public offering to raise up to $74.8 million.
Monster Digital Inc. has signed a definitive merger agreement with privately held Innovate Biopharmaceuticals Inc., prompting 160 percent gain in its stock price Monday.
Amgen Inc.’s metastatic colorectal cancer drug Vectibix won approval for a label expansion from the U.S. Food and Drug Administration, the company announced Thursday.
Apollo Medical Holdings Inc. reported widening losses despite higher revenue in its most recent fiscal year.
MannKind Corp. on Thursday announced it has agreed to extend the due date of a $10 million loan owed to Deerfield Management Co. from July 2017 to October 2017.
MannKind Corporation on Wednesday announced that it has requested a final loan disbursement of $30.1 million from the Mann Group.